Novartis’s (NVS) parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites was granted FDA orphan ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as Zolgensma, could be approved for a broad range of spinal muscular atrophy ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

In this trial, the efficacy and safety of the therapy were evaluated against a sham control in treatment-naïve SMA Type 2 ...

Novartis has been among the largest so far in 2025, with plans to cut 427 jobs at its East Hanover site. The pharmaceutical ...

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...

Swiss pharmaceutical giants Roche and Novartis are revising their diversity policies in response to recent U.S. executive ...

In the time since the Novartis gene therapy Zolgensma was approved for babies with spinal muscular atrophy, other treatments ...

Novartis (NVS) announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene ...